Innovus Pharmaceuticals Inc (OTCMKTS:INNV) On A Bull Run

Innovus Pharmaceuticals Inc (OTCMKTS:INNV) has been on a bull run in 2016 with shares up more than 10 fold. Shares have really turned into a runner this month on the back of press releases and positive news from the company. Judging by the jump in volume, the move higher might just be getting started.Innovus Pharma describes itself as "an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum+® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), (f) Zestra Glide®, (g)Vesele® for promoting sexual and cognitive health, (i) Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA."The latest news showed that first quarter revenues increased 15% from $196k to $225k. Net assets increased from $6.3m to $6.7m. Net loss decreased from $.04 to $.02 per share. CEO Dr Damaj said of the results:

"Innovus is a Company with multiple areas of expansion, progress and growth. As a result of our FlutiCare™ ANDA under review by the FDA, our increasing revenues, our continuous product acquisition, our entry into new markets and the planned uplist to the NYSE-MKT, first quarter 2016 has been a high growth quarter for the Company. Investors are starting to realize the value of our products, business strategy and growth plans. Our execution of our business plan is meticulous, concise and it is working."

One of the main factors that's been driving shares higher has been the company's talk of an uplisting to NYSEMKT. This would be a huge deal if it happened because it's not an easy thing to do. However, INNV feels confident that it can get it accomplished. What was notable was what the company said in the press release about its CEO.

Innovus Pharma management has a strong CEO who knows how to work with higher exchanges at previous companies like Apricus Biosciences (previously known as NexMed). At Apricus Biosciences, he transitioned the company from being deficient in every listing requirement with the NASDAQ exchange to being compliant in all requirements in less than a year after he took over the helm in 2009 (Source:APRI SEC filings). Under his leadership, Apricus went from $0.17 a share to over $5 and was named one of the most liquid companies NASDAQ. The company went on to be included in the Russell Microcap Index.

Dr Damaj's track record certainly helps and he looks to be building another success story with Innovus. INNV already has 13 commercial products already on the market. The company has been generating sales from its products for two consecutive years. Innovus has ten signed commercial partnerships that could open the door to $500 million in potential sales milestones plus royalties in 60 countries -- a move that could make 2016 a year of record growth. In addition, the company is awaiting approval for its FlutiCare™ OTC drug (a GlaxoSmithKline Flonase competitor) for allergic rhinitis, a market that exceeds 1 billion dollars.Innovus also acquired Beyond Human assets in March of 2016, which had revenues of $1.3 million in 2013 and $2.2 million in 2014. With the new acquisition under its belt, the company added a natural Testosterone booster and a natural Human Growth Agent to its product portfolio. The acquisition should also be accretive over the near-term since the private company generated some $400,000 in net profits in 2015 - up from $300,000 the year prior.INNV recently raised $2.5 million in growth capital and repaid all of its outstanding debt, which puts the company on solid financial footing. This year, the company plans to become cash flow positive, and in 2017, it hopes to be profitable. INNV already has significant distribution in the United States through Walmart, Target, Walgreen's Drugstore.com, and numerous other retailers which will allow these developments to happen. We will be updating Insider Financial as soon as we know more. For continuing coverage on INNV, sign up for our free newsletter today and get our next hot stock pick!Disclosure: We have no position in INNV and have not been compensated for this article.